Month: June 2025

Nanterre, 6 June 2025 VINCI opens the A57 motorwayFollowing widening into a dual three-lane carriageway A vital link carrying an average of 110,000 vehicles a day A €300 million investment financed by VINCI AutoroutesVINCI Autoroutes has opened in Toulon the new A57 motorway following its widening into a dual three-lane carriageway. This large-scale project, worth €300 million and entirely financed by VINCI Autoroutes under Escota’s concession contract, has radically upgraded this motorway in southern France, which carries an average of 110,000 vehicles a day. The development has freed up traffic and considerably improved safety, while encouraging the use of public transport and multimodal travel by providing alternatives to solo driving. Revamping this 7 km urban motorway section through Toulon, La Valette-du-Var and La Garde...

$1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants TORONTO, June 06, 2025 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 434,720 shares of common stock at a purchase price of $2.65 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered short-term warrants to purchase up to 869,440 shares of common stock at an exercise price of $2.65 per share that will be immediately exercisable upon issuance and will expire eighteen months following the effective...

LAS VEGAS, June 06, 2025 (GLOBE NEWSWIRE) — Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced that its indirectly wholly owned subsidiary askROI, Inc. (“askROI”), has officially launched an advanced Artificial Intelligence (“AI”) Agent designed to transform customer service operations across industries. The new AI-powered agent leverages state-of-the-art natural language processing and machine learning capabilities to deliver real-time, context-aware support to customers on a 24/7 basis. Built with enterprise scalability, security, and flexibility at its core, the askROI AI Agent empowers businesses to improve response times, boost customer satisfaction, and significantly reduce support costs. Key features of the AI Agent:Natural Language Understanding:...

Data featured in oral presentation and poster session at 48th European Cystic Fibrosis Conference WALTHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) — Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the presentation of preclinical data that demonstrate that the company’s nucleotide-binding domain 1 (NBD1) stabilizers, in dual combinations with proprietary complementary modulators, enable full CFTR correction in CF models. The data are featured in an oral presentation and poster session at the European Cystic Fibrosis Society (ECFS) 48th European Cystic Fibrosis Conference...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange notice from IDEX Biometrics ASA (the “Company”) on 21 May 2025 regarding the commencement of the subscription period (the “Subscription Period”) in the subsequent offering (the “Subsequent Offering”) consisting of up to 600,000,000 new shares (the “Offer Shares”) in the Company at a subscription price of NOK 0.01 per share (“Offer Price”). The Subscription Period commenced on 22 May 2025 and expired on 5 June...

Booth #5389 + AVIXA TV Studio: Experience Real-Time Multilingual Translation at ScaleInfoComm 2025 x AI-MediaVisit AI-Media at InfoComm 2025, Booth #5389NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) — AI-Media (ASX: AIM), the global leader in AI-powered language solutions, will debut its game-changing LEXI VOICE platform at InfoComm 2025, setting a new benchmark for live, multilingual accessibility. Attendees can visit Booth #5389 or tune in via AVIXA TV Studio to witness how LEXI VOICE instantly translates spoken content into natural-sounding audio across 100+ languages – redefining how the world connects.  Following its acclaimed launch at NAB Show 2025, LEXI VOICE combines ultra-accurate live captioning, AI-driven translation, and lifelike voice synthesis to deliver seamless, simultaneous multilingual output in real...

Series  RIKB 27 0415 RIKB 35 0917Settlement Date  06/12/2025 06/12/2025Total Amount Allocated (MM)  1,550 5,130All Bids Awarded At (Price / Yield)  100.735 / 7.530 100.325 / 6.950Total Number of Bids Received  11 22Total Amount of All Bids Received (MM)  1,815 6,300Total Number of Successful Bids  8 17Number of Bids Allocated in Full  8 17Lowest Price / Highest Yield Allocated  100.735 / 7.530 100.325 / 6.950Highest Price / Lowest Yield Allocated  100.825 / 7.480 100.560 / 6.920Lowest Price / Highest Yield Allocated in Full  100.735 / 7.530 100.325 / 6.950Weighted Average of Successful Bids (Price/Yield)  100.771 / 7.510 100.448 / 6.930Best Bid (Price / Yield)  100.825 / 7.480 100.560 / 6.920Worst Bid (Price / Yield)  100.700 / 7.560 100.100 / 6.980Weighted Average of All Bids Received (Price...

– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. – LOS ANGELES, CA, June 06, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it was selected by FDA, and attended, the FDA CEO forum led by FDA Commissioner Marty A. Makary, M.D., M.P.H. and team at FDA headquarters in Silver Spring, MD, on June 5, 2025.  Per FDA, the purpose of the meeting is to gather direct input from biotechnology and pharmaceutical leaders on how the FDA can modernize its regulatory framework to better support innovation and patient access to safe and effective therapies. FDA Commissioner Marty A. Makary, M.D., M.P.H. stated, “These...